Dr. Mark G. Kris from Memorial Sloan-Kettering cancer center Explains How Gene Signatures are Used
Mark G. Kris, MD, FASCO
Advertisement
Articles by Mark G. Kris, MD, FASCO
Dr. Mark G. Kris thoracic chair at Memorial Sloan-Kettering Cancer Center Discusses Driver Mutations Test False Negatives
Dr. Mark G. Kris from Memorial Sloan-Kettering on Integrating Driver Mutation Testing Study Results
Dr. Mark G. Kris from memorial sloan-kettering Talks About the importance of Defining the broad term Biomarkers
Dr. Mark Kris from MSKCC Describes the Genetic Mutation Screening Multicenter Study
Dr. Kris from Memorial Sloan-Kettering Discusses Tests Available for Lung Cancer
Dr. Mark Kris from Memorial Sloan-Kettering Cancer Center Discusses the Pemetrexed Clincal Trial Results
Dr. Kris From Memorial Sloan-Kettering Cancer Center Discusses the Imatinib GIST Clinical Trial
Dr Kris From Memorial Sloan-Kettering Cancer Center Discusses Methotrexate in Acute Lymphocytic Leukemia
Dr. Kris From Memorial Sloan-Kettering Cancer Center on the Use of Genetic Testing in Lung Cancer
Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York on the EML4-ALK Translocation
Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center on the Crizotinib Clinical Trials
Dr. Mark G. Kris from Memorial Sloan-Kettering on Caring for Elderly Lung Cancer Patients
Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York Discusses EGFR Mutation Testing
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
5